![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Independent Nutrition Logic Ltd, Wymondham, Norfolk NR18 0QX, UK
Many hypotheses of disease risk and prevention depend on inferences about the metabolic effects of fructose; however, there is inadequate attention to dose dependency. Fructose is proving to have bidirectional effects. At moderate or high doses, an effect on any one marker may be absent or even the opposite of that observed at very high or excessive doses; examples include fasting plasma triglyceride, insulin sensitivity, and the putative marker uric acid. Among markers, changes can be beneficial for some (e.g., glycated hemoglobin at moderate to high fructose intake) but adverse for others (e.g., plasma triglycerides at very high or excessive fructose intake). Evidence on body weight indicates no effect of moderate to high fructose intakes, but information is scarce for high or excessive intakes. The overall balance of such beneficial and adverse effects of fructose is difficult to assess but has important implications for the strength and direction of hypotheses about public health, the relevance of some animal studies, and the interpretation of both interventional and epidemiological studies. By focusing on the adverse effects of very high and excessive doses, we risk not noticing the potential benefits of moderate to higher doses, which might moderate the advent and progress of type-2 diabetes, cardiovascular disease, and might even contribute to longevity. A salutary rather than hyperbolic examination of the evidence base needs to be undertaken.
* To whom correspondence should be addressed. E-mail: glivesey{at}inlogic.co.uk.
This article has been cited by other articles:
|
|
 |
|
  S. P. Murphy The State of the Science on Dietary Sweeteners Containing Fructose: Summary and Issues to Be Resolved J. Nutr., June 1, 2009; 139(6): 1269S - 1270S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Jones Dietary Sweeteners Containing Fructose: Overview of a Workshop on the State of the Science J. Nutr., June 1, 2009; 139(6): 1210S - 1213S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. White Misconceptions about High-Fructose Corn Syrup: Is It Uniquely Responsible for Obesity, Reactive Dicarbonyl Compounds, and Advanced Glycation Endproducts? J. Nutr., June 1, 2009; 139(6): 1219S - 1227S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Moran Fructose and Satiety J. Nutr., June 1, 2009; 139(6): 1253S - 1256S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Bantle Dietary Fructose and Metabolic Syndrome and Diabetes J. Nutr., June 1, 2009; 139(6): 1263S - 1268S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Schaefer, J. A. Gleason, and M. L. Dansinger Dietary Fructose and Glucose Differentially Affect Lipid and Glucose Homeostasis J. Nutr., June 1, 2009; 139(6): 1257S - 1262S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Angelopoulos, J. Lowndes, L. Zukley, K. J. Melanson, V. Nguyen, A. Huffman, and J. M. Rippe The Effect of High-Fructose Corn Syrup Consumption on Triglycerides and Uric Acid J. Nutr., June 1, 2009; 139(6): 1242S - 1245S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Marriott, N. Cole, and E. Lee National Estimates of Dietary Fructose Intake Increased from 1977 to 2004 in the United States J. Nutr., June 1, 2009; 139(6): 1228S - 1235S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. L. Stanhope and P. J. Havel Fructose Consumption: Considerations for Future Research on Its Effects on Adipose Distribution, Lipid Metabolism, and Insulin Sensitivity in Humans J. Nutr., June 1, 2009; 139(6): 1236S - 1241S. [Abstract] [Full Text] [PDF]
|
|
